<DOC>
	<DOCNO>NCT00005855</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : This phase I/II trial study side effect best dose efaproxiral give carmustine see well work treat patient progressive recurrent malignant glioma .</brief_summary>
	<brief_title>Efaproxiral Plus Carmustine Treating Patients With Progressive Recurrent Malignant Glioma</brief_title>
	<detailed_description>OBJECTIVES : - Evaluate safety tolerability escalate dos efaproxiral ( RSR13 ) administer concurrently carmustine patient progressive recurrent malignant glioma . - Determine maximum tolerate dose ( MTD ) RSR13 administer carmustine patient population . - Determine pharmacokinetic profile regimen patient . - Estimate efficacy regimen MTD patient . OUTLINE : This nonrandomized , open-label , multicenter , dose-escalation study efaproxiral ( RSR13 ) . Patients receive RSR13 IV 30 minute follow 30 minute later carmustine IV 1-2 hour day 1 . Treatment repeat every 6 week maximum 6 course absence unacceptable toxicity disease progression . Cohorts 6-12 patient receive escalate dos RSR13 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 3 6 5 12 patient experience dose-limiting toxicity . Once MTD determine , additional patient accrue receive treatment RSR13 carmustine recommend phase II dose . Patients follow 6 week every 2 month thereafter . PROJECTED ACCRUAL : A maximum 48 patient accrued phase I portion study . A maximum 47 patient accrue phase II portion study .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Efaproxiral</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignant glioma progressive recurrent radiotherapy without chemotherapy Anaplastic astrocytoma Anaplastic oligodendroglioma Glioblastoma multiforme Prior lowgrade glioma allow provide progression occur radiotherapy without chemotherapy highgrade glioma find biopsy Measurable disease serial MRI CT scan PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Hemoglobin least 10 g/dL Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 2.0 mg/dL Alkaline phosphatase great 3 time upper limit normal ( ULN ) SGOT SGPT great 3 time ULN Renal : Creatinine great 2.0 mg/dL Pulmonary : Resting oxygen saturation room air least 90 % pulse oximetry FVC , DLCO , FEV_1 least 50 % normal Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No serious concurrent medical illness would preclude study compliance No prior malignancy within past 5 year except curatively treat basal cell squamous cell skin cancer carcinoma situ PRIOR CONCURRENT THERAPY : Biologic therapy : At least 3 week since prior investigational biologics Chemotherapy : See Disease Characteristics No prior nitrosoureas glioma No 1 prior chemotherapy regimen At least 4 week since prior chemotherapy No prior efaproxiral Endocrine therapy : Concurrent corticosteroid ( e.g. , dexamethasone ) allow Radiotherapy : See Disease Characteristics At least 90 day since prior radiotherapy Surgery : Not specify Other : At least 3 week since prior investigational drug device</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2003</verification_date>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>